Genetic Technologies Limited announced the appointment of Ms. Kathryn Andrews as Chief Financial Officer commencing immediately. Kathryn is a highly experienced biotechnology executive with both ASX and Nasdaq experience most recently as CFO for Alterity Therapeutics between November 2014 and February 2024. Between 2012 and 2014, Kathryn held a senior role with The CFO Solution, a firm focused on providing an outsourced CFO team including company secretarial to listed public companies, mainly in the biotechnology sector.

Between 2002 and 2006 Kathryn was the CFO and Company Secretary of Antisense Therapeutics Limited.